Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.
Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.
Terminalia arjuna, commonly known as arjuna, that belongs to the family of Combretaceae. Most
 clinical and experimental studies for Terminalia arjuna, have suggested that the crude drug
 possesses anti-ischemic, antioxidant, hypolipidemic, and antiatherogenic activities.
Inclusion Criteria:

 -  1. Participant of either sex, aged ≥ 30 to ≤ 70 years at the time of screening
 (completed). 2. Participants with normal to high normal blood pressure (BP) [systolic
 BP ≥ 120 and ≤ 139 mm Hg and/or diastolic BP ≥ 80 and ≤ 89 mm Hg] as defined by "The
 Task Force for the management of arterial hypertension of the European Society of
 Cardiology (ESC) and the European Society of Hypertension (ESH)". 3. Participants with
 normal to mildly deranged 'Left ventricular ejection' as per as per American College
 of Cardiology: LVEF ≥ 39 and ≤ 55%. 4. BMI ≥ 25 to ≤ 34.9 kg/m2 5. Normal level of
 Aspartate transaminase (AST) and Alanine transaminase (ALT) as specified by reference
 range of College of American Pathologists certified laboratory. 6. Normal level of
 Creatinine as specified by reference range of College of American Pathologists
 certified laboratory. 7. Participants must have demonstrated their willingness to
 participate in the study and comply with the study procedures and required visits. 8.
 Willing to abstain from caffeine, alcohol and related products consumption 12 hours
 prior to study visits. 9. Those having the ability to understand and sign a written
 informed consent form, which must be completed prior to study specific requirements
 being performed. 10. Must be literate and have the ability to complete the study-based
 questionnaires and requirements. 11. Female participants of childbearing age must be
 willing to use the accepted methods of contraception during the study.

 Exclusion Criteria:

 -  Systolic BP ≥140 mm Hg and/ or Diastolic BP ≥ 90 mm Hg. 2. Fasting blood sugar ≥ 126
 mg/dL 3. Presence of any unstable, acutely symptomatic, or life-limiting illness. 4.
 History or presence of clinically significant renal, hepatic, endocrine, biliary,
 gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the
 investigator, would interfere with the participant's ability to provide informed
 consent, comply with the study protocol (that might confound the interpretation of the
 study results), or put the participant at undue risk. 5. Using Omega fish oil
 supplements, anticonvulsants, Coenzyme Q10, Vitamin K2, proton pump inhibitors, loop
 diuretics, anticoagulants, barbiturates, anti-epileptic medications and any herbal
 supplements (e.g. flax seeds, chia seeds). 6. Chronic use of anti-inflammatory
 medications (≥ 5 tablets/20 days in last 3 months). 7. Individuals having a history of
 smoking or currently smoking and also using any form of smokeless tobacco. 8.
 High-risk drinking as defined by consumption of 4 or more alcohol containing beverages
 on any day or 8 or more alcohol containing beverages per week for women and 5 or more
 alcohol containing beverages on any day or 15 or more alcohol containing beverages per
 week for men. 9. Binge drinkers as defined by consumption of 4 or more alcohol
 containing beverages for women and 5 or more alcohol containing beverages for men
 within 2 hours. 10. Abnormal thyroid stimulating hormone (TSH) levels beyond the
 defined reference range (<0.4 and > 4.0 IU/ml) 11. Participants unable to walk. 12.
 Participants with history of chronic caffeine use. 13. Participants who have any other
 disease or condition, or are using any medication, that in the judgment of the
 investigator would put him/her at unacceptable risk for participation in the study or
 may interfere with evaluations in the study or noncompliance with treatment or visits.
 14. Females who are pregnant/planning to be pregnant/lactating or taking any oral
 contraceptives. 15. Females undergoing hormone replacement treatments. 16. Menopausal
 females having less than 3 years of menopausal history 17. Those unwilling to abstain
 from other dietary supplements or medication (e.g. Hepatoprotective agents and other
 traditional medicines - Ayurveda, Siddhi, Chinese herbal medicine, Naturopathy). 18.
 Have participated in a study of an investigational product 90 days prior to the
 screening. 19. Participants with known or suspected hypersensitivity or intolerance to
 Investigational product. 20. Participants who are unable to comply with study
 requirements. 21. Any clinical signs or symptoms that in the opinion of investigator,
 can jeopardize the outcome of the study.